GlassScriptPhysician profile
Ian S Elliot
NPI 1649277328
$3,898.74
in general payments reported to CMS, 2019-2025
15 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $1,074 · 2021: $778 · 2022: $126 · 2023: $962 · 2024: $438 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,572.30 | 2021-2024 | Inbone, Augment Injectable, Infinity Adaptis |
| Tandem Diabetes Care, INC. | $1,503.27 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $232.60 | 2019-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $154.23 | 2020-2022 | |
| Horizon Therapeutics Plc | $118.09 | 2021 | |
| Lilly USA, LLC | $86.05 | 2023-2024 | Jardiance, Lyumjev |
| Novo Nordisk INC | $61.75 | 2019-2023 | Ozempic |
| Medtronic, INC. | $36.19 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $34.59 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $20.91 | 2024 | Unithroid |
| Abbvie INC. | $19.10 | 2023 | |
| Boston Scientific Corporation | $18.69 | 2023 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $16.63 | 2025 | Tepezza |
| Shire North American Group INC | $13.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Elliot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.